CD274 and neoplasm: Whereas, only a few patients benefit from immunotherapy, and the current prognostic factors, including tumour mutation burden (TMB), microsatellite instability (MSI), and PD‐1/PD‐L1 expression, are insufficient for accurately predicting immunotherapeutic response.4, 5